For this purpose, for more than two decades we have maintained excellent relationships with a number of Japanese pharmaceutical companies, such as Takeda Pharmaceuticals Company Limited, which is Japan’s leading pharmaceuticals manufacturer. Besides the Japanese connection, since 2000 the company has been making inroads to the USA, which today is the largest pharmaceuticals market, and home to the leading companies engaged in original research. We currently maintain R&D partnerships with two companies:

At the end of 2004, and in November 2005, we signed a total of three research agreements with US-based Forest Laboratories, which, although regarded as a mid-sized company in terms of its sales revenue, has an outstanding track record with respect to the clinical development and US distribution of compounds that act on the central nervous system. Within the framework of this partnership we are jointly continuing the clinical development of our RGH-896 (Radiprodil) pain-reliever, the RGH-188 (Cariprazine) antipsychotic.

Also in 2004, we signed a cooperation agreement with the Japanese Mitsubishi Pharmaceuticals corporation, regarding the joint development of Cariprazine.

We plan to sign additional cooperation agreements in the future, and to this end we are continuously examining opportunities for forming partnerships with European, American and Japanese partners.